HOWARD COHEN

Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.

Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.

Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid rebate and best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price.

Issues relating to the implementation of Medicare Drug Negotiations.

Issues relating to the implementation of Medicare Drug Negotiations.

Issues relating to the implementation of Medicare Drug Negotiations.

Issues relating to Medicare Part D and Part B Reimbursement and Benefit Design in Inflation Reduction Act.

Issues relating to the design of Medicare Part D and Part B reimbursement of drugs and biologics in the Inflation Reduction Act.

Issues relating to the design of Medicare Part D and Part B reimbursement of drugs and biologics in the Inflation Reduction Act.

Issues relating to Medicare Part D and Part B Reimbursement and Benefit Design in Inflation Reduction Act.

Issues relating to Part D and Part B Reimbursement and Benefit Design in Build Back Better Reconciliation Bill.

Reimbursement and Design Issues for Medicare Part D and Part B Drugs in the Build Back Better Reconciliation Bill.

Issues relating to the design and reimbursement of Part D and Part B drugs in the Build Back Better Reconciliation Bill.

Issues relating to Part D and Part B Reimbursement and Benefit Design in Build Back Better Reconciliation Bill.

Reimbursement and Design Issues for Medicare Part D and Part B Drugs in the Build Back Better Reconciliation Bill.

Issues relating to the design and reimbursement of Part D and Part B drugs in the Build Back Better Reconciliation Bill.

Issues relating to Part D and Part B benefit design in Reconciliation Bills.

Issues relating to the design and reimbursement of Part D and Part B drugs in Reconciliation Bills.

Reimbursement and Design Issues for Medicare Part D and Part B drugs in Reconciliation Bills.

Issues relating to Part D and Part B benefit design.

Issues relating to the design and reimbursement of Part D and Part B drugs.

Reimbursement and Design Issues for Medicare Part D and Part B drugs.

Issues relating to the design and reimbursement of Part D and Part B drugs.

Reimbursement and Design Issues for Medicare Part D and Part B drugs.

Issues relating to Part D and Part B benefit design.

Issues concerning the Part D drug benefit and Final Rebate Pass Through Rule.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies under CMMI Most Favored Nation Interim Final Rule.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies.

Issues concerning the Part D drug benefit.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS. Issues concerning Home Administerd Incident-To Drugs in Medicare.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments). lssues involving demonstrations for home health administered incident-to drugs in Medicare. Issues involving Medicaid Best Price and Accumulators.

Issues concerning the Part D drug benefit.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments). lssues involving demonstrations for home health administered incident-to drugs in Medicare.

Issues concerning the Part D drug benefit.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS. Issues concerning Home Administerd Incident-To Drugs in Medicare.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Issues concerning the Part D drug benefit.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments). lssues involving CMMI demonstrations and Section 402 demonstrations.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments). lssues involving CMMI demonstrations and Section 402 demonstrations.

Issues concerning the Part D drug benefit.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments). lssues involving CMMI demonstrations and Section 402 demonstrations.

Issues concerning the Part D drug benefit.

Issues regarding Part D benefit design and formulary development. Part B Demonstration Projects in CMMI of CMS.

Issues concerning the Part D drug benefit.

Lobbying on issues involving: the Part D Medicare prescription drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues concerning Section 1927 (Medicaid drug benefit and payments).

Issues regarding Part D coverage and discounts in the donut hole of the Part D benefit and modifications in the attachment point of the catastrophic benefit of Part D. Part B CMMI demonstration Project.

Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues concerning Federal Grants for Hospitals for Emergency Relief due to damage from floods and hurricanes.

Issues involving the Part D Medicare Prescription Drug Benefit: the discount rate for drugs inside the Part D donut hole; and the calculation of the catastrophic drug coverage attachment point for Part D..

Lobbying on issues involving: the Part D Medicare Prescription Benefit specifically related to the Part D donut hole discount percentage and TROOP and the catastrophic attachment point for the drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues involving Section 1927 -- Medicaid Drug Benefit and Rebates.

Issues regarding Part D coverage and discounts in the donut hole of the Part D benefit and modifications in the attachment point of the catastrophic benefit of Part D.

Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues concerning Federal Grants for Hospitals for Emergency Relief due to damage from floods and hurricanes.

Lobbying on issues involving: the Part D Medicare Prescription Benefit specifically related to the Part D donut hole discount percentage and TROOP and the catastrophic attachment point for the drug benefit; issues relating to Part B demonstrations and alternative payment methodologies; and issues involving Section 1927 -- Medicaid Drug Benefit and Rebates.

Issues involving the Part D Medicare Prescription Drug Benefit: the discount rate for drugs inside the Part D donut hole; and the calculation of the catastrophic drug coverage attachment point for Part D..

Lobbying on issues involving involving the Part D Medicare Prescription Benefit and Medicaid Section 1927 issues involving line extensions.

Issues involving the Part D Medicare Prescription Drug Benefit.

Issues regarding Part D coverage and discounts

Lobby issues concerning Federal Grants for Hospitals for Emergency Relief due to damage from floods and hurricanes.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues concerning Federal Grants for Hospitals for Emergency Relief due to damage from floods and hurricanes.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Issues relating to CMMI demonstration project on Part B drugs and biologics and Medicaid Provisions of the Repeal and Replace Bills. Issues regarding Part D coverage and discounts

Lobbying on issues involving involving the Part D Medicare Prescription Benefit and Medicaid Section 1927 issues involving line extensions.

Issues involving the stability fund in the House and Senate Repeal and Replace Health Care Bills.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues relating to health care coverage and Medicaid of the American Health Care Act of 2017.

Lobbying on issues involving involving the stability funds and Medicaid in the House and Senate Repeal and Replace Health Care Bills.

Issues involving the stability fund in the House and Senate Repeal and Replace Health Care Bills.

Issues relating to CMMI demonstration project on Part B drugs and biologics and Medicaid Provisions of the Repeal and Replace Bills.

Issues relating to CMMI demonstration project on Part B drugs and biologics and Medicaid Provisions of the Repeal and Replace Bills.

Lobby issues relating to health care coverage and Medicaid of the American Health Care Act of 2017.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Issues involving the stability fund in the House and Senate Repeal and Replace Health Care Bills.

Lobbying on issues involving involving the stability funds and Medicaid in the House and Senate Repeal and Replace Health Care Bills.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues relating to health care coverage and Medicaid of the American Health Care Act of 2017.

Issues relating to CMMI demonstration project on Part B drugs and biologics and Medicaid Provisions of the Repeal and Replace Bills.

Lobbying on issues involving involving the stability funds and Medicaid in the House and Senate Repeal and Replace Health Care Bills.

Issues involving the stability fund in the House and Senate Repeal and Replace Health Care Bills.

Lobby issues concerning Medicaid per capita caps and enhanced Medicaid match in the American Health Care Act of 2017. Lobby issues concerning the productivity adjuster to hospital payment rates in Medicare.

Lobby issues relating to health care coverage and Medicaid of the American Health Care Act of 2017.

Issues relating to CMMI demonstration project on Part B drugs and biologics.

Lobbying on issues involving CMMI demonstration project on Part B drugs.

Reimbursement issues for Hospitals in Medicare, Medicaid, and the Health Care Exchanges created by the ACA.

Reimbursement issues for Hospitals in Medicare, Medicaid, and the Health Care Exchanges created by the ACA.

Issues relating to and CMMI demonstration project on Part B drug demonstration.

Lobbied on the issues of CMMI and the Part B demonstration project.

Issues relating to and CMMI demonstration project on Part B drug demonstration.

Lobbied on the issues of CMMI and the Part B demonstration project.

Issues relating to payment for innovative and follow-on biologics and demonstration projects at CMS.

Issues related to Medicare payment for mental health services to psychiatrists.

Issues involving dual eligible plans and Medicare Advantage.

Issues relating to health care exchanges.

Issues relating to payment for innovative and follow-on biologics and demonstration projects at CMS.

Issues relating to health care exchanges.

Issues involving dual eligible plans and Medicare Advantage.

Issues related to Medicare payment for mental health services to psychiatrists.

Medicaid and Medicare Drug Benefit: Coverage and Reimbursement. Issues involving the FDA on industry user fees and FDA regulation of drugs and biologics. Issues involving drug benefit coverage in ACA Exchange Plans.

Medicaid and Medicare Drug Benefit: Coverage and Reimbursement. Issues involving the FDA on industry user fees and FDA regulation of drugs and biologics. Issues involving drug benefit coverage in ACA Exchange Plans.

Medicaid and Medicare Drug Benefit: Coverage and Reimbursement. Issues involving the FDA on industry user fees and FDA regulation of drugs and biologics. Issues involving drug benefit coverage in ACA Exchange Plans.

Issues relating to payment for innovative and follow-on biologics.

Issues relating to health care exchanges.

Issues involving dual eligible plans and Medicare Advantage.

Issues relating to Medicare payment for mental health services to psychiatrists.

Issues relating to mental health parity and severe mental illness.

Issues relating to payment for innovative and follow-on biologics.

Issues relating to Medicare payment for mental health services to psychiatrists.

Issues relating to mental health parity and severe mental illness.

Issues involving dual eligible plans and Medicare Advantage.

Issues relating to health care exchanges.

Issues involving dual eligible plans and Medicare Advantage.

Issues relating to health care exchanges.

Issues relating to Medicare payment for mental health services to psychiatrists.

Issues relating to mental health parity and severe mental illness.

Issues relating to health care exchanges.

Issues involving dual eligible plans and Medicare Advantage.

Issues relating to Medicare payment for mental health services to psychiatrists.

Issues relating to mental health parity and severe mental illness.

Issues regarding payments of psychiatrists in Medicare and Medicaid and mental health parity.

Issues regarding payments of psychiatrists in Medicare and Medicaid and mental health parity.

Issues relating to health care exchanges.

Issues involving Medicaid dual eligible plans and Medicare Advantage.

Issues relating to the regulatory and statutory payment of home health services in the Medicare fee for service program.

Issues involving Medicaid dual eligible plans and Medicare Advantage.

Issues relating to health care exchanges.

Issues regarding actuarial scoring of combined Medicare A and B for Fee-For-Service Medicare. Scoring issues regarding value based benefit design

Issues relating to the regulatory and statutory payment of Home Health Services in the Medicare fee-for-service program.

Issues involving the Affordable Care Act concerning health insurance exchanges and premiums for health plans.

Issues involving Medicare Advantage and the Medicaid program.

Issues regarding actuarial scoring of combined Medicare A and B for fee-for-service Medicare benefit.

Issues relating to value based insurance design on health insurance benefit design.